From tumor size and HER2 status to systems oncology for very early breast cancer treatment

References

• Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ; Panel members. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann. Oncol.20(8), 1319–1329 (2009).
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Guidelines for Treatment of Cancer by Site. National Comprehensive Cancer Network, PA, USA (2009).
   Google Scholar
• Burstein HJ. The distinctive nature of HER2-positive breast cancers. N. Engl. J. Med.353(16), 1652–1654 (2005).
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N. Engl. J. Med.353(16), 1734–1736 (2005).
   PubMed Web of Science ®Google Scholar
• Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature458(7239), 719–724 (2009).
   PubMed Web of Science ®Google Scholar
• Shendure J, Ji H. Next-generation DNA sequencing. Nat. Biotechnol.26, 1135–1145 (2008).
   PubMed Web of Science ®Google Scholar
• Friedman A, Perrimon N. Genetic screening for signal transduction in the era of network biology. Cell128, 225–231 (2007).
   PubMed Web of Science ®Google Scholar
• Deisboeck TS. Personalizing medicine: a systems biology perspective. Mol. Syst. Biol.5, 249 (2009).
   PubMedGoogle Scholar
• Roukos DH. Novel clinico–genome network modelling for revolutionizing genotype-phenotype-based personalized cancer care. Exp. Rev. Mol. Diagn.10(1), 33–48 (2010).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Angulo AM, Litton JK, Broglio KR et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J. Clin. Oncol.27(34), 5700–5706 (2009).
   PubMed Web of Science ®Google Scholar
• Curigliano G, Viale G, Bagnardi V. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J. Clin. Oncol.27(34), 5693–5699 (2009).
   PubMed Web of Science ®Google Scholar
• Joensuu H, Isola J, Lundin M et al. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin. Cancer Res.9(3), 923–930 (2003).
   PubMed Web of Science ®Google Scholar
• Black D, Younger J, Martei Y et al. Recurrence risk in T1a-b, node-negative, HER2 positive breast cancer. Breast Cancer Res. Treat.100(Suppl. 1), S92 (2006) (Abstract 2037).
   Google Scholar
• Rakkhit R, Broglio K, Peintinger F et al. Significant increased recurrence rates among breast cancer patients with HER2 positive, T1a-b,N0M0 tumors. Cancer Therapy and Reseach Center at University of Texas – American Association for Cancer Research Breast Cancer Symposium, San Antonio, TX, December 10–14, (2008). Cancer Res.69(Suppl.), S96 (2009) (Abstract 701).
   Google Scholar
• Joensuu H, Kellokumpu-Lehtinen P-L, Bono P et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med.354(8), 809–820 (2006).
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med.353(16), 1659–1672 (2005).
   PubMed Web of Science ®Google Scholar
• Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med.353(16), 1673–1684 (2005).
   PubMed Web of Science ®Google Scholar
• Slamon D, Eiermann W, Robert N et al. BCIRG 006: 2nd interim analysis Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in HER2/neu positive early breast cancer patients. Presented at: 29th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 14–17 December 2006.
   Google Scholar
• Tuttle TM, Habermann EB, Grund EH, Morris TJ, Virnig BA. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J. Clin. Oncol.25(33), 5203–5209 (2007).
   PubMed Web of Science ®Google Scholar
• Roukos DH. Radiation therapy for breast cancer. N. Engl. J. Med.360(13), 1362 (2009).
   PubMedGoogle Scholar
• Roukos DH. Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann. Surg. Oncol.17, 14–17 (2010).
   PubMed Web of Science ®Google Scholar
• Viani G, Afonso S, Stefano E et al. Adjuvant trastuzumab in the treatment of HER-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer7, 153 (2007).
   PubMed Web of Science ®Google Scholar
• de Boer M, van Deurzen CH, van Dijck JA et al. Micrometastases or isolated tumor cells and the outcome of breast cancer. N. Engl. J. Med.361(7), 653–663 (2009).
   PubMed Web of Science ®Google Scholar
• Roukos DH. Isolated tumor cells in breast cancer. N. Engl. J. Med.361, 1994–1995 (2009).
   PubMedGoogle Scholar
• Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N. Engl. J. Med.360(8), 790–800 (2009).
   PubMed Web of Science ®Google Scholar
• Roukos DH. Twenty-one-gene assay: challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer. J. Clin. Oncol.27(8), 1337–1338 (2009).
   PubMedGoogle Scholar
• Fisher B, Dignam J, Tan-Chiu E et al. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. J. Natl Cancer Inst.93, 112–120 (2001).
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet365, 1687–1717 (2005).
   PubMed Web of Science ®Google Scholar
• Miller DG. On the nature of susceptibility to cancer. The presidential address. Cancer46, 1307–1318 (1980).
   PubMedGoogle Scholar
• Schinzel AC, Hahn WC. Oncogenic transformation and experimental models of human cancer. Front. Biosci.13, 71–84 (2008).
   PubMedGoogle Scholar
• Wood LD, Parsons DW, Jones S. The genomic landscapes of human breast and colorectal cancers. Science318(5853), 1108–1113 (2007).
   PubMed Web of Science ®Google Scholar
• Jones S, Zhang X, Parsons DW. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science321(5897), 1801–1806 (2008).
   PubMed Web of Science ®Google Scholar
• Bastiaens P. Systems biology: when it is time to die. Nature459(7245), 334–335 (2009).
   PubMed Web of Science ®Google Scholar
• Liu S, Dontu G, Mantle ID et al. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res.66, 6063–6071 (2006).
   PubMed Web of Science ®Google Scholar
• Prasad CP, Gupta SD, Rath G et al. Wnt signaling pathway in invasive ductal carcinoma of the breast: relationship between β-catenin, disheveled and cyclin D1 expression. Oncology73, 112–117 (2007).
   Google Scholar
• Farnie G, Clarke R. Mammary stem cells and breast cancer – role of notch signaling. Stem Cell Rev.3, 169–175 (2007).
   PubMed Web of Science ®Google Scholar
• Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA100, 3983–3988 (2003).
   PubMed Web of Science ®Google Scholar
• Singh SK, Hawkins C, Clarke ID et al. Identification of human brain tumour initiating cells. Nature432, 396–401 (2004).
   PubMed Web of Science ®Google Scholar
• O’Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature445, 106–110 (2007).
   PubMed Web of Science ®Google Scholar
• Ricci-Vitiani L, Lombardi DG, Pilozzi E et al. Identification and expansion of human colon-cancer-initiating cells. Nature445, 111–115 (2007).
   PubMed Web of Science ®Google Scholar
• Schatton T, Murphy GF, Frank NY et al. Identification of cells initiating human melanomas. Nature451, 345–349 (2008).
   PubMed Web of Science ®Google Scholar
• Pommier SJ, Quan GG, Christante D et al. Characterizing the HER2/neu status and metastatic potential of breast cancer stem/progenitor cells. Ann. Surg. Oncol. DOI: 10.1245/s10434-009-0730-z (2009) (Epub ahead of print).
   Google Scholar
• Tomasson MH. Cancer stem cells: a guide for skeptics. J. Cell. Biochem.106(5), 745–749 (2009).
   Google Scholar
• Eaves CJ. Cancer stem cells: here, there, everywhere? Nature456(7222), 581–582 (2008).
   PubMed Web of Science ®Google Scholar